Novo Nordisk's future in doubt after Wegovy maker's 'surprise' CEO ouster

Novo Nordisk's surprise ousting of CEO Lars Fruergaard Jørgensen, despite a tripling of the share price during his tenure, has sparked analyst concern regarding the future of its Wegovy obesity drug amid rising competition and recent stock declines of over 50% since summer 2024. While some analysts commend Novo for addressing shortcomings, the timing, coinciding with the imminent end of compounding pharmacy competition, is questioned, with speculation arising about the company's broader challenges and potential strategic shift toward regaining market share, possibly through an American CEO to navigate the U.S. market.

Analysis

Novo Nordisk's abrupt announcement of CEO Lars Fruergaard Jørgensen's departure has introduced considerable uncertainty, perplexing analysts despite his eight-year tenure marked by a significant strategic pivot towards obesity drugs and a tripling of the share price. The company cited concerns over losing market leadership for its Wegovy drug as the rationale, coming at a time when the stock has declined over 50% since summer 2024, attributed to competition from U.S. drug compounders and disappointing trial results for next-generation treatments. Analyst commentary reflects this bemusement: Sydbank termed it a "gigantic surprise," acknowledging recent challenges but also Jørgensen's successes, and questioned if underlying issues are more severe than disclosed. Deutsche Bank expressed "mixed feelings," commending accountability but finding the timing "haphazard," especially with a May 22 deadline looming for compounding pharmacies to cease selling copies. Barclays' Emily Field found the timing particularly confusing given Novo's typically conservative approach and the imminent resolution of the compounding issue. Conversely, J.P. Morgan viewed the change positively, as a decisive move by the Novo Nordisk Foundation to reposition for the GLP-1 market opportunity. The stock initially fell 1.8% before recovering 2.5%, reflecting the market's mixed reaction. Speculation includes the potential hiring of an American CEO to navigate U.S. market complexities, including drug pricing pressures, and broader concerns about undisclosed operational challenges.

Key Decisions for Investors

• Investors should closely monitor developments in the CEO search for indications of strategic shifts, particularly regarding U.S. market penetration and competitive responses to Eli Lilly.
• Evaluate the impact of the May 22 deadline for compounding pharmacies on Wegovy sales and assess if this regulatory change mitigates the concerns that ostensibly led to the CEO's ousting.
• Re-assess risk exposure to Novo Nordisk given the heightened leadership uncertainty, recent share price volatility, and analyst concerns over potentially undisclosed challenges, despite the long-term growth narrative in the obesity market.